Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2

First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at the World Vaccine Conference on April 3rd 2024 in Washington, DC BILTHOVEN, The Netherlands, March 26, 2024 (GLOBE NEWSWIRE) -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive clinical data of a first in human (FIH)

Related Keywords

Australia ,Washington ,United States ,Bilthoven ,Utrecht ,Netherlands ,Dinja Oosterhoff ,Research Development ,Administration Of The Avacc ,World Vaccine Conference ,Jan Groen ,Utrecht Science Park Bilthoven ,Homv ,Subunit Vaccine ,Therapeutic Vaccines ,Immune Response ,Mucosal Immune Response ,Igg Antibodies ,Clinical Data ,Clinical Study ,Intranasal ,First In Human ,Booster Vaccine ,Research And Development ,